Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PTGES2 divergent transcript (PTGES2-DT, also known as PTGES2-AS1 or PTGES2 antisense RNA 1) is a long non-coding RNA (lncRNA) gene located at the PTGES2 genomic locus, transcribed in the opposite direction ("head-to-head" antisense) relative to the PTGES2 gene. Unlike PTGES2, which encodes a membrane-associated enzyme involved in prostaglandin E2 synthesis, PTGES2-DT does not code for a protein. Its specific biological function, clinical significance, and disease associations remain uncharacterized, and there are no known drugs or therapeutics targeting this non-coding RNA. This transcript should not be confused with the protein-coding PTGES2 or with small-molecule drug targets[7]. If you are seeking information on the prostaglandin E synthase 2 enzyme (PTGES2, a therapeutic target in inflammation and cancer), please refer to its associated entries, as PTGES2-DT is a distinct, non-coding RNA with no current evidence of therapeutic relevance or established biological function[2][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PTGES2 antisense RNA 1 (head to head) (PTGES2-AS1).